U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
SEC
File Number: 000-54554
[
] Form 10-K [ ] Form 20-F
[ ] Form 11-K [X] Form 10-Q
[ ] Form 10-D [
] Form N-SAR [ ] Form N-CSR
For period ended:
March 31, 2020
[
] Transition Report on Form 10-K
[
] Transition Report on Form 20-F
[
] Transition Report on Form 11-K
[
] Transition Report on Form 10-Q
[
] Transition Report on Form N-SAR
For the Transition
Period Ended: N/A
|
Nothing in this
form shall be construed to imply that the Commission has verified
any information contained herein.
|
|
PART I -
REGISTRANT INFORMATION
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
|
Full Name of
Registrant:
|
|
4093 Oceanside
Boulevard, Suite B
|
Address of Principal
Executive Office
|
|
Oceanside,
California 92056
|
City, State and Zip
Code
|
PART II - RULES
12b-25 (b) AND (c)
If
the subject report could not be filed without unreasonable effort
or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed.
[X]
|
(a)
|
The
reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
|
|
|
(b)
|
The
subject annual report, semi-annual report, transition report on
Form 10-K, Form 20-F, 11-K or Form N-SAR or Form N-CSR, or portion
thereof, will be filed on or before the fifteenth calendar day
following the prescribed due date; or the subject quarterly report
or transition report on Form 10-Q, or portion thereof, will be
filed on or before the fifth calendar day following the prescribed
due date; and
|
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c)
has been attached, if applicable.
|
PART III -
NARRATIVE
Therapeutic Solutions International, Inc. (the “Company”) will
continue to rely on the Securities and Exchange Commission’s Order
under Section 36 of the Securities Exchange Act of 1934 Granting
Exemptions From Specified Provisions of the Exchange Act and
Certain Rules Thereunder dated March 25 Order (Release No.
34-88465) (the “Order”) to delay the filing of its Quarterly Report
on Form 10-Q for the period ended March 31, 2020 (the “Report”) due
to the circumstances related to COVID-19. In particular, COVID-19
has caused severe disruptions in transportation and limited access
to the Company’s facilities resulting in limited support from its
staff and professional advisors. This has, in turn, delayed the
Company’s ability to complete its audit and prepare the Report. The
Company filed an 8-K on May 29, 2020 disclosing that it expected to
file the Report no later than June 29, 2020 (which is 45 days from
the Report’s original filing deadline of May 15, 2020). Due
to continued delays caused by COVID-19 that continue to cause
severe disruptions in transportation and limited access to the
Company’s facilities resulting in limited support from its staff
and professional advisors, the 10-Q will be filed on or before the
fifth calendar day following the extended due date not falling on a
holiday or weekend, which would be July 6, 2020.
In light of the current COVID-19 pandemic, the Company will be
including the following Risk Factor in its Report:
An occurrence of an uncontrollable event such as the COVID-19
pandemic may negatively affect our operations.
The occurrence of an uncontrollable
event such as the COVID-19 pandemic may negatively affect our
operations. A pandemic typically results in social distancing,
travel bans and quarantine, and this may limit access to our
facilities, customers, management, support staff and professional
advisors. These factors, in turn, may not only impact our
operations, financial condition and demand for our goods and
services but our overall ability to react timely to mitigate the
impact of this event. Also, it may hamper our efforts to comply
with our filing obligations with the Securities and Exchange
Commission.
PART IV - OTHER
INFORMATION
(1)Name
and telephone number of person to contact in regard to this
notification
Timothy G. Dixon
|
|
760
|
|
295-7208
|
(Name)
|
|
(Area
Code)
|
|
(Telephone Number)
|
(2)Have
all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such
shorter period that the registrant was required to file such
report(s) been filed? If the answer is no, identify
report(s).
[X] Yes [ ] No
(3)Is
it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject
report or portion thereof?
[
] Yes [X] No
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.
|
(Name
of Registrant as Specified in Charter)
|
has caused this
notification to be signed on its behalf by the undersigned hereunto
duly authorized.
Date:
May 29, 2020By: /s/ Timothy G.
Dixon
Name: Timothy G. Dixon
Title: Chief Executive Officer